Jeroncellevain, a company specializing in the production of prescription pharmaceuticals, announced on June 2 that it participated as a speaker at the 2025 Korean Society for Stem Cell and Tissue Regeneration Spring Academic Conference, where it gave a lecture on the mechanism of action and tissue regeneration effects of its PDRN-based prescription drug, Cellvain Injection.
The 2025 Korean Society for Stem Cell and Tissue Regeneration Conference was held on June 1 at Songbong Hall, Chung-Ang University Hospital. Renowned domestic biomedical scientists and clinical researchers attended the event to share and present the latest innovative technologies and research findings in the field of stem cells and tissue regeneration.
Kim Deokgyu, CEO of Jeroncellevain, delivered a presentation on "The Latest Insights on PDRN and the Relationship Between PDRN and Stem Cells," focusing on the functions and mechanisms of polydeoxyribonucleotide (PDRN), as well as the safety and efficacy of the company's product, Cellvain Injection, and highlighted its potential applications.
In particular, Cellvain Injection is a product that does not use chemical substances, based on the company's proprietary patented technology, Prism Technology (Prism-T). Medical professionals and related stakeholders attending the conference visited the promotional booth and showed interest in the product.
Kim Deokgyu, CEO of Jeroncellevain, stated, "PDRN has attracted attention in the domestic aesthetics market due to its outstanding regenerative effects, but we have also conducted research from a medical treatment perspective and developed our own product." He emphasized, "PDRN promotes the recovery of damaged tissue and activates the adenosine A2A receptor, and its effectiveness is superior when the molecular weight is small and consistent."
He added, "This conference was a great opportunity to actively introduce our product to numerous medical professionals in Korea. We will continue to do our best to launch even safer and more effective products in the future."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
